EnteroMedics has obtained a committed issuer managed equity financing facility under which it may from time to time sell up to $45 million of its registered common stock to Terrapin Opportunity, L.P., over a 24-month period.
EnteroMedics is not obligated to utilize any of the $45 million facility and remains free to enter into and consummate other equity and debt financing transactions, subject to certain restrictions.
For further deal information visit Current Agreements (subscription required)
Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary
Read: latest life science partnering, M&A, financing and deal talk updates
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Financing Scorecard – view top life science financing deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity